Previous close | 2.1500 |
Open | 2.2800 |
Bid | 2.1300 |
Ask | 2.5700 |
Strike | 195.00 |
Expiry date | 2026-01-16 |
Day's range | 2.1500 - 2.2800 |
Contract range | N/A |
Volume | |
Open interest | 1.14k |
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their...
Insightful Analysis of Shockwave Medical's Position in the Cardiovascular Device Market
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. These data were featured at the 2024 American Urological Association (AUA) Annual Meeting. Results featured updated data from Cohort 1 (C1),